Modified GRF(1-29)
Evidence: CGH Axis / Body Composition
Evidence Snapshot
What this grade covers
C reflects confidence in the identity-boundary distinction between Modified GRF(1-29)/"CJC-1295 without DAC" marketplace material and CJC-1295 DAC -- established through FDA's 2024 identity-evidence-gap review and independent LC-HRMS seized-product analytical findings (Gajda et al. 2019, PMID 30136411) showing genuine product-identity heterogeneity in this market segment -- not through direct evidence of the marketplace material's own pharmacology. Direct human efficacy, pharmacokinetic, or safety evidence for Modified GRF(1-29)/CJC-1295-without-DAC itself remains limited to absent in this package. DAC-conjugated CJC-1295 human/preclinical evidence (Jette 2005, Teichman 2006, Ionescu/Frohman 2006) is comparator and development-history context only and does not support Modified GRF(1-29) efficacy, PK, safety, or dosing claims. There is no FDA-approved therapeutic indication for this subject. No dosing or performance inference should be drawn from any source in this package.
Regulatory Context
Investigational and not FDA-approved. FDA’s 2024 review identified CJC-1295 free base and acetate as distinct from DAC forms and found major identity, characterization, efficacy, and safety-data gaps.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
A label used for short-acting GHRH analog products lacking the DAC albumin-binding moiety; exact chemical identity may vary by source.
Why are researchers interested in it?
Discussed as a short-acting GH-releasing analog, but the standalone identity and evidence base are frequently conflated with Modified GRF(1-29) or DAC CJC-1295.
What does the evidence look like?
Very limited and identity-confounded. FDA found major inconsistencies in nomenclature and noted that clinical references submitted for non-DAC nominations referred to the DAC active moiety.
Biggest things to know
This page should remain on hold until canonical identity is resolved. The Jetté 2005 albumin-bioconjugate paper belongs to CJC-1295 DAC and should not support a non-DAC page.
Research Takeaway
CJC-1295 free base/no-DAC is a synthetic 29-amino-acid GHRH analogue and is a distinct active moiety from CJC-1295 DAC, which contains an albumin-binding drug-affinity-complex modification.
Evidence boundary: The name CJC-1295 is used inconsistently in commerce and literature, so identity must be established from the actual molecular form rather than the label name alone.
See all 7 evidence claims →Quick Summary
“CJC-1295 without DAC” is a marketplace label that is often equated with Modified GRF(1-29), but the naming is not consistently used in scientific and commercial sources. FDA’s 2024 review distinguished CJC-1295 free base or acetate from DAC forms and found that the available clinical references largely concerned CJC-1295 DAC. A separate evidence base for the non-DAC product as commonly sold was not established.
Mechanism & Research Overview
FDA materials distinguish CJC-1295 free base and acetate from CJC-1295 DAC forms as different active moieties. The non-DAC forms are described as modified 29-amino-acid GHRH analogs, but direct pharmacology, identity, characterization, efficacy, and safety data are limited. Commercial terms such as “Modified GRF(1-29)” should not be treated as automatically interchangeable without product-specific identity verification.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
CJC-1295 free base/no-DAC is a synthetic 29-amino-acid GHRH analogue and is a distinct active moiety from CJC-1295 DAC, which contains an albumin-binding drug-affinity-complex modification.
Does not establish
Evidence boundary: The name CJC-1295 is used inconsistently in commerce and literature, so identity must be established from the actual molecular form rather than the label name alone.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps; Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Supported
Published human CJC-1295 pharmacology commonly cited for prolonged GH and IGF-I elevation studied the DAC-containing long-acting form and cannot be transferred as direct human efficacy evidence to CJC-1295 free base/no-DAC.
Does not establish
Evidence boundary: This is an evidence-separation claim, not evidence that non-DAC CJC-1295 has no biological activity.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps; Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults
Supported
CJC-1295 free base/no-DAC is not an FDA-approved drug, and FDA has documented substantial nomenclature, characterization, and compounding concerns across CJC-1295-related bulk substances.
Does not establish
Evidence boundary: Compounding review or nomination does not constitute FDA approval.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps; Drugs@FDA: FDA-Approved Drugs Database
Supported
FDA reported that clinical safety information was not found for CJC-1295 free base or CJC-1295 acetate in its reviewed nominations and literature and highlighted peptide-quality and identity risks.
Does not establish
Evidence boundary: Absence of adequate safety data is not proof of specific toxicity, but it precludes a claim of established human safety.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps
Supported
Claims about prolonged half-life, days-long GH elevation, or sustained IGF-I elevation from DAC CJC-1295 must not be presented as established properties of CJC-1295 no-DAC.
Does not establish
Evidence boundary: The two active moieties have different structural designs and evidence bases.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps; Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults
Supported
Only dosing explicitly tied to a named preclinical or clinical source may appear as Study/Trial Dosing; no consumer GH-enhancement, bodybuilding, reconstitution, mixing, or injection protocol is authorized.
Does not establish
Evidence boundary: The frozen package contains no validated consumer dosing regimen for non-DAC CJC-1295.
Sources: FDA Evaluation of CJC-1295 Free Base and Acetate: Identity and Evidence Gaps; Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Supported
Marketplace/vendor naming of 'CJC-1295 without DAC' as equivalent to a single, uniformly defined 'Modified GRF(1-29)' sequence does not establish chemical equivalence across products; analytical testing (LC-HRMS) of seized doping-market material identified glycine-modified GRF(1-29) variants distinct from the sequence commonly described in vendor/marketplace literature, indicating genuine product-identity heterogeneity in this market segment.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
The marketplace term may not reliably identify one canonical active moiety, salt, or sequence. This prevents confident linkage of studies, dosing, and safety data.Higher-Priority Safety Consideration
FDA’s review found that clinical references supplied in nominations concerned DAC forms rather than the non-DAC free base or acetate.Higher-Priority Safety Consideration
Inconsistent naming can result in a product, reference standard, or study being attributed to the wrong CJC-1295 form.Higher-Priority Safety Consideration
As with other synthetic injectable peptides, aggregation, impurities, sterility, endotoxin control, and immunogenicity are relevant concerns.Safety Consideration
There is insufficient verified human exposure information for the non-DAC identity commonly marketed under this name.
Research Areas Being Studied
Research areas discussed on this page reflect the GH Axis / Body Composition category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Modified GRF(1-29) identified in seized products | 2019 | Seized/marketplace product samples analyzed for peptide identity | Analytical (LC-MS-based) testing identified modified GRF(1-29) sequences in seized product samples marketed under CJC-1295-related names, directly illustrating the identity/naming inconsistency this page's advisory addresses. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| 2026 World Anti-Doping Agency Prohibited List | 2026 | Anti-doping regulatory standard | WADA lists growth-hormone-releasing factors and secretagogues, including CJC-1295, sermorelin, GHRP-2, GHRP-6, and examorelin/hexarelin, as prohibited in sport. | Anti-doping status is not a clinical safety or efficacy determination. | |
| Drugs@FDA: FDA-Approved Drugs Database | 2026 | Current Drugs@FDA name searches performed for this frozen package did not identify approved drug products under the names AHK-Cu, FOXO4-DRI, Pinealon, or Mechano Growth Factor. A negative name search does not exclude differently named products but establishes that no approval was identified under these research names. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational research summary only. This page does not provide medical advice, treatment guidance, product-quality assurance, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-12.
Follow research updates for Modified GRF(1-29)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.